1. Validation of the 2017 revision of the WHO chronic myelomonocytic leukemia categories
by Sanam Loghavi, Dawen Sui, Peng Wei, Guillermo Garcia-Manero, Sherry Pierce, Mark J. Routbort, Elias J. Jabbour, Naveen Pemmaraju, Rashmi Kanagal-Shamanna, H. Deniz Gur, Shimin Hu, Zhuang Zuo, L. Jeffrey Medeiros, Hagop M. Kantarjian, and Joseph D. Khoury
BloodAdv
Volume 2(15):
August 14, 2018
© 2018 by The American Society of Hematology

2. Sanam Loghavi et al. Blood Adv 2018;2:1807-1816
© 2018 by The American Society of Hematology

3. Distribution of CMML patients across categories in the 2008 and 2017 WHO classification schemes.
Sanam Loghavi et al. Blood Adv 2018;2:
© 2018 by The American Society of Hematology

4. Outcome comparisons for MDS-CMML and MP-CMML.
Outcome comparisons for MDS-CMML and MP-CMML. Kaplan-Meier plots for OS (A) and cumulative incidence of AML (B) in treatment-naïve patients stratified by WHO 2008 and 2017 WBC count (FAB-based MP and MDS subgroups)–based subgroups.
Sanam Loghavi et al. Blood Adv 2018;2:
© 2018 by The American Society of Hematology

5. Outcome comparisons for 2008 and 2017 blast-based subgroups.
Outcome comparisons for 2008 and 2017 blast-based subgroups. Kaplan-Meier plots for OS (A,C) and cumulative incidence of AML (B,D) in treatment-naïve patients stratified by blast-based subgroups.
Sanam Loghavi et al. Blood Adv 2018;2:
© 2018 by The American Society of Hematology